| Literature DB >> 24598046 |
Danilo Buonsenso1, Giovanni Barone, Piero Valentini, Filomena Pierri, Riccardo Riccardi, Antonio Chiaretti.
Abstract
BACKGROUND: We performed a prospective, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of a sedation protocol based on intranasal Ketamine and Midazolam (INKM) administered by a mucosal atomizer device in uncooperative children undergoing gastric aspirates for suspected tuberculosis. PRIMARY OUTCOME: evaluation of Modified Objective Pain Score (MOPS) reduction in children undergoing INKM compared to the placebo group. SECONDARY OUTCOMES: evaluation of safety of INKM protocol, start time sedation effect, duration of sedation and evaluation of parents and doctors' satisfaction about the procedure.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24598046 PMCID: PMC3974003 DOI: 10.1186/1471-2431-14-67
Source DB: PubMed Journal: BMC Pediatr ISSN: 1471-2431 Impact factor: 2.125
Figure 1The Mucosal Atomiser Device (MAD) used to deliver medications via a fine spray in the nasal cavity.
Figure 2Patients allocation (CONSORT).
Age, start times, end times and duration of the sedation effect in children undergoing procedural sedation by intranasal Midazolam and Ketamine and MOPS achieved in both the sedation and placebo groups
| 41.5 | 24.2 to 58.9 | 31.0 | 18.8 to 49.3 | 36.0 | 13 | 168 | |
| 40.6 | 21.3 to 59.9 | 33.0 | 19.2 to 48.7 | 34.8 | 14 | 152 | |
| 22.9 | 19.2 to 26.6 | 24 | 15.4 to 26.6 | 13.7 | 6 | 60 | |
| Na# | na | na | na | na | na | | |
| 77.9 | 70.1 to 85.7 | 80 | 75.0 to 84.0 | 29.2 | 30 | 180 | |
| Na | na | na | na | na | na | Na | |
| 71.5 | 63.8 to 79.3 | 72.0 | 65.6 to 76.6 | 28.9 | 25 | 176 | |
| Na | na | na | na | na | na | Na | |
| 3.5 | 3.1 to 3.9 | 4.0 | 3.0 to 4.0 | 1.6 | 1 | 8 | |
| 7.2 | 6.9 to 7.6 | 7 | 7.0 to 8.0 | 1.4 | 4 | 9 | |
*p <0.0001.
#na: not applicable due to no effects of placebo.
Parents’ and medical doctors’ responses to the questionnaire on the administration of intranasal Ketamine and Midazolam (table A) and placebo (table B) via a mucosal atomiser device
| Helped | 19 | 10 | 10-10 | 5/3 | 10 | 10-10 |
| Level of child’s outlook | 19 | 8.9 | 7-10 | 5/3 | 8 | 7-9 |
| Level of parents’ outlook | 19 | 9.1 | 8-10 | 5/3 | 9.5 | 9-10 |
| Level of doctors’ outlook | - | - | | 5/3 | 8.5 | 8-10 |
| Level of child’s tolerance of procedures | 19 | 8.7 | 7-10 | 5/3 | 8.2 | 7-9 |
| Would recommend to other parents | 19 | 9.3 | 9-10 | - | - | |
| Would recommend to other doctors | - | - | | 5/3 | 9.4 | 9-10 |
| Would like to see MAD used routinely | 19 | 9.8 | 9-10 | 5/3 | 10 | 10 |
| Made the procedure more acceptable | - | - | - | 5/3 | 10 | 10 |
| Helped | 19 | 5 | 3-7 | 5/3 | 3 | 2-4 |
| Level of child’s outlook | 19 | 5.8 | 5-7 | 5/3 | 3 | 2-4 |
| Level of parents’ outlook | 19 | 4.9 | 3-7 | 5/3 | 5 | 3-7 |
| Level of doctors’ outlook | - | - | | 5/3 | 4 | 3-5 |
| Level of child’s tolerance of procedures | 19 | 8.5 | 7-10 | 5/3 | 8 | 7-9 |
| Would recommend to other parents | 19 | 4 | 3-6 | - | - | |
| Would recommend to other doctors | - | - | | 5/3 | 3 | 1-5 |
| Would like to see MAD used routinely | 19 | 4 | 3-6 | 5/3 | 3 | 1-5 |
| Made the procedure more acceptable | - | - | - | 5/3 | 3 | 1-5 |
*unbiased medical doctors involved in the painful or diagnostic procedures (text for details).
INKM, intranasal midazolam and ketamine.
MAD, mucosal atomiser device.